Clinical-stage gene therapy company Genprex Inc (NASDAQ: GNPX) announced on Monday that positive preclinical data on its lead candidate, Reqorsa Gene Therapy, will be presented at the 2024 EORTC-NCI-AACR Symposium, taking place from 23-25 October 2024 in Barcelona.
The data focuses on Reqorsa's potential as a treatment for Ras inhibitor-resistant lung cancer, mesothelioma and glioblastoma.
Collaborators, including the University of Texas MD Anderson Cancer Center and New York University Langone Health, will showcase studies demonstrating that Reqorsa's TUSC2 gene therapy overcomes resistance in KRAS mutant lung cancer and suppresses tumour growth in mesothelioma and glioblastoma. Two provisional patent applications have been filed based on these findings.
Reqorsa, which uses Genprex's Oncoprex Delivery System, specifically targets cancer cells with the TUSC2 gene, delivering promising preclinical results.
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Carisma and Moderna expand collaboration
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Cantargia reports promising data for nadunolimab in cancer treatment